NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
November 23, 2004 • Volume 1 / Number 45 E-Mail This Document  |  View PDF Version  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Model Predicts Follicular Lymphoma Survival

Director's Update
Achieving Success and Addressing Challenges in Tobacco Control

Special Report
Family Studies: Unlocking Genetic Secrets, Promoting Team Science

Cancer Research Highlights
NCI Funds EDRN Labs to Sustain Biomarker Discovery

BRCA1 Mutation Increases Sensitivity to Chemotherapy

Inverse Association Found Between Selenium and Colorectal Cancer

Immunosuppressant Drug May Increase Risk of Lymphoma

Community Update
New NCI Booklet Explains Biological Therapy

Funding Opportunities

Featured Clinical Trial
Vaccine Therapy for Advanced Prostate Cancer

Notes
Rowland to Appear on CBS's Sunday Morning

Waldmann Lectures on Role of IL-2 and IL-15 in Immunotherapy

ASCO Issues Clinical Recommendations on Aromatase Inhibitors

FDA Approves Tarceva for Non-Small-Cell Lung Cancer

Featured Meetings

Bulletin Archive

Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
View/Print PDF  View/Print PDF
Funding Opportunities Funding Opportunities

NCI Transition Career Development Award to Promote Diversity
PAR-05-011
Application Receipt Dates: Jan. 10, May 10, Sept. 10, 2005;
Jan. 10, May 10, Sept. 10, 2006;
Jan. 10, May 10, Sept. 10, 2007

The NCI Transition Career Development Award to Promote Diversity (K22) will provide "protected time" for recipients to develop and receive support for their initial cancer research program. This award will facilitate the transition of underrepresented postdoctoral research scientists from the mentored to the independent stages of their careers in cancer research. Past patterns of cancer incidence and mortality predict that a disproportionate share of the increase in U.S. cancer incidence and mortality will be borne by minorities. A major obstacle to developing a stronger national minority cancer research effort has been the lack of significant strategic training programs for minority students and scientists in cancer research. The K22 mechanism establishes a unique pathway for recruiting and retaining advanced postdoctoral students and new investigators from groups that are underrepresented in biomedical research into investigative fields that address problems pertinent to the biology, etiology, pathogenesis, prevention, diagnosis, control, and treatment of human cancer. This funding opportunity will use the Transition Career Development Award (K22) mechanism.

For more information see: http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2420

Inquiries: Belinda M. Locke - lockeb@mail.nih.gov

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov